Switching between Wegovy and Zepbound, and who is really deciding

Most people searching this did not choose to switch. A formulary chose for them. CVS Caremark removed Zepbound in July 2025 and told members they would have to try and fail Wegovy first, then said it would add Zepbound back as a preferred option on 1 October 2026, so a lot of people are being pushed one way and invited back the other inside fourteen months. Here is what your plan will ask for when you switch in either direction, and what each side costs today.

Julian CaraulaniFounder, PriceTracker GLP-1Last checked Aug 28We track prices. Clinical facts on this site are quoted from the drug's label, the FDA or the published trial, with the source and the date beside each one. We do not write medical guidance and we do not tell anyone what to take.

6 min read · published Aug 28

The short version

1Most switches are formulary-driven rather than chosen, and the direction has reversed inside fourteen months.
2Switching to a non-preferred brand needs a documented trial of the preferred one: drug, duration, dose, outcome.
3They are different molecules, so dosing restarts rather than converting. That is your prescriber's call, not a chart's.
4Caremark adds Zepbound back as a preferred option on 1 October 2026, which may make the switch unnecessary.

Start with an uncomfortable question: is this your decision?

Plenty of people arrive at this switch because a letter told them to. In July 2025 CVS Caremark, which runs the formulary for Aetna among others, told members:¹

As of July 1, 2025, Wegovy will be the preferred formulary option for obesity treatment. … All members, regardless of indication, will need to have tried and failed Wegovy before they can access tirzepatide.
CVS Caremark

Then, fourteen months later:²

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026
CVS Health

In plain English

Same benefit manager, opposite instructions, inside fourteen months. If you are on Caremark and considering the switch to Zepbound right now, the cheapest move may be to wait for 1 October, because a formulary exception you fight for in September becomes unnecessary in October. Adoption varies by plan, so confirm yours rather than assuming.

What your plan asks for when you switch

Moving to a brand your formulary does not prefer needs a documented trial of the one it does. The Federal Employee Program puts the requirement plainly:³

Patient MUST have tried the preferred product(s) … unless the patient has a valid medical exception
BCBS Federal Employee Program

What "tried" means in practice is four specifics in your chart, and vagueness here is what sinks these requests:

Which drug, by brand name.
For how long, with dates.
At what dose, including whether you reached a maintenance dose or stopped during titration.
What happened: inadequate response, intolerance, or a contraindication. These are the three words the criteria use, so they are the words worth using.

The instrument is a formulary exception, filed by your prescriber. It is a different process from an appeal, and asking for the right one saves a week.

The clinical part is not ours to answer

Semaglutide and tirzepatide are different molecules with different labels, so this is not a dose conversion. Your prescriber decides where you start on the new drug and how you get there, and anyone publishing a neat equivalence table between the two is overstepping.

What we can tell you is what to bring to that conversation: your current dose, how long you have been on it, what results you have had, and any side effects that shaped the decision. If you want the published ladders for each, we keep them alongside what each step costs, in the semaglutide chart and the Wegovy chart.

What each side costs

If coverage is what is pushing the switch, cost is worth checking in both directions before you commit to the paperwork.

Novo publishes a flat cash price for the Wegovy pen across every standard dose:⁴

then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy HD 7.2 mg
NovoCare Pharmacy

And the compounded market sits below both brands, with the trade-off that compounded products are not FDA-approved:

A point people miss when a formulary forces a switch: the cash price of the drug you are being pushed off may be lower than the post-card price of the one you are being pushed onto. Work out your own number rather than assuming coverage wins. The manufacturer cards cap out at $100 a month off, which is not the same as the $25 they advertise.

Before you start the paperwork

Check whether you have to. On Caremark plans, Zepbound becomes a preferred option on 1 October 2026, and adoption varies by plan.
Get the trial documented properly if you do: drug, duration, dose, outcome.
Ask for the criteria document, so you are answering the actual test rather than guessing at it.
Price both sides, including the cash route, before deciding the covered drug is the cheap one.

Your insurer's verified position on both brands is in our coverage tracker, and if the request comes back denied, which kind of no you got decides what is worth doing next.

Sources4

CVS Caremark, formulary change communicated to plan members read Aug 20“As of July 1, 2025, Wegovy will be the preferred formulary option for obesity treatment. … All members, regardless of indication, will need to have tried and failed Wegovy before they can access tirzepatide.” ↩
CVS Health, Zepbound returning to commercial formularies read Aug 20“CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026” ↩
Blue Cross Blue Shield Federal Employee Program, Zepbound policy read Aug 20“Patient MUST have tried the preferred product(s) … unless the patient has a valid medical exception” ↩
NovoCare Pharmacy, self-pay prices read Aug 27“then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy HD 7.2 mg” ↩

Common questions

Why is my insurance making me switch from Zepbound to Wegovy?

Because your formulary prefers Wegovy. CVS Caremark removed Zepbound from its commercial formularies on 1 July 2025 and told members that all of them, regardless of indication, would need to have tried and failed Wegovy before accessing tirzepatide. That is a formulary decision made by the pharmacy benefit manager rather than a clinical judgement about you.

Can I switch back from Wegovy to Zepbound?

Usually yes, with a documented trial of the preferred drug: which brand, for how long, at what dose, and whether the outcome was inadequate response, intolerance or a contraindication. Your prescriber files it as a formulary exception. On Caremark plans it may also become unnecessary, since Zepbound returns as an additional preferred option on 1 October 2026, with adoption varying by plan.

How do I convert my Wegovy dose to Zepbound?

You do not convert it. Semaglutide and tirzepatide are different molecules with separate labels and separate titration schedules, so your prescriber decides your starting dose on the new drug rather than translating the old one. Bring your current dose, how long you have been on it, your results and any side effects to that conversation.

Is Zepbound or Wegovy cheaper without insurance?

Novo publishes a flat $349 a month for the Wegovy pen at every standard dose and $399 for the 7.2 mg high-dose pen. Compare that against the current cash price for tirzepatide rather than assuming, and note that compounded programs for both molecules sit below either brand, with the trade-off that they are not FDA-approved.

Does switching restart my prior authorization?

Generally yes. A new drug means a new authorisation with its own criteria and its own approval period, and renewal typically depends on results, commonly around 5 percent weight loss from baseline. Ask for a recorded baseline weight before you start the new drug rather than reconstructing it later.